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BACKGROUND: Dysregulation of the cell cycle is a hallmark of many cancers including ovarian cancer, a leading cause of gynaecologic
cancer mortality worldwide.
METHODS: We examined single nucleotide polymorphisms (SNPs) (n¼288) from 39 cell cycle regulation genes, including cyclins,
cyclin-dependent kinases (CDKs) and CDK inhibitors, in a two-stage study. White, non-Hispanic cases (n¼829) and ovarian
cancer-free controls (n¼941) were genotyped using an Illumina assay.
RESULTS: Eleven variants in nine genes (ABL1, CCNB2, CDKN1A, CCND3, E2F2, CDK2, E2F3, CDC2, and CDK7) were associated
with risk of ovarian cancer in at least one genetic model. Seven SNPs were then assessed in four additional studies with 1689 cases
and 3398 controls. Association between risk of ovarian cancer and ABL1 rs2855192 found in the original population [odds ratio,
ORBB vs AA 2.81 (1.29–6.09), P¼0.01] was also observed in a replication population, and the association remained suggestive in the
combined analysis [ORBB vs AA 1.59 (1.08–2.34), P¼0.02]. No other SNP associations remained suggestive in the replication
populations.
CONCLUSION: ABL1 has been implicated in multiple processes including cell division, cell adhesion and cellular stress response. These
results suggest that characterization of the function of genetic variation in this gene in other ovarian cancer populations is warranted.
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Ovarian cancer is the seventh most common cancer and the fourth
leading cause of cancer death in women worldwide (Parkin et al,
2005). With the highest mortality of all gynaecological malig-
nancies, 15520 deaths were estimated in the US in 2008 (American
Cancer Society, 2008). The pathogenesis and progression of
ovarian cancer is not well understood, which contributes to its
poor survival, along with difficulties in early detection among
asymptomatic women. Modifiable risk factors, which are few,
include oral contraceptives, family history and age at menarche.
Known genetic risk factors are restricted to mutations inherited in
the high risk, high penetrant genes (e.g. BRCA1/2 and DNA
mismatch repair genes), which are rare in the general popu-
lation and estimated to account for no greater than 10–15%
of ovarian cancer (Chen et al, 2006; Lancaster et al, 2007).
Owing to a consensus that genetic factors have a function in
susceptibility to ovarian cancer, studies targeting specific path-
ways in ovarian cancer case–control studies have emerged
(Dicioccio et al, 2004; Auranen et al, 2005; Beesley et al, 2007;
Song et al, 2007; Mann et al, 2008; Pearce et al, 2008; Quaye
et al, 2008) and some report nominally significant associations
with ovarian cancer risk (Buller et al, 1997; Berchuck et al, 2004;
Dicioccio et al, 2004; Kelemen et al, 2008; Pearce et al, 2008;
Sellers et al, 2008).
Dysregulation of the cell cycle is a hallmark of many cancers
(Pharoah et al, 2007; Butt et al, 2008; Nam and Kim, 2008) and
control and timing of the cell cycle involves checkpoints and
regulatory pathways that ensure the fidelity of DNA replication
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sand chromosome segregation (Elledge, 1996). These processes
involve a large collection of key molecules, which are excellent
candidates for ovarian cancer susceptibility variants. These include
the cyclins (CCNA1, CCNA2, CCNB1, CCNB2, CCND1, CCND2,
CCND3, CCNE1, CCNE2, CCNG1, CCNG2), cyclin-dependent
kinases (CDKS: CDK2, CDK4, CDK6, CDK7, CDC2), CDK inhibitors
(CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CDKN2D) and
CDC2 regulators (CDC25A, CDC25B). The catalytic subunit of
CDKs is activated by one of many activating subunits, the cyclins.
Cyclin levels oscillate during the cell cycle, and cyclin–CDK
complexes finely regulate progression through the cell cycle.
Inhibitors of CDK promote cell cycle arrest and may affect
response to mitogenic stimuli. In addition to the cyclins, CDKs and
CDK inhibitors, the E2 family of transcription factors is a critical
element as well as the E2F family’s dimerization partners TFDP1,
TFDP2, CUL1 and SKP2, which are involved in the SCF ubiquitin
ligase complex. In addition, Rb (and two Rb-like genes) regulates
progression of cells from G1 to S to G2 phases. CCND, CCNE and
E2F are over-expressed in a variety of cancer, including ovarian
cancer (D0Andrilli et al, 2004), and data emanating from an
immunohistochemical study of ovarian cancer (Hashiguchi et al,
2004) reveals alteration of G2 in ovarian cancer specimens. The
SCF ubiquitin ligases are well-characterized mammalian cullin
RING ubiquitin ligases (Frescas and Pagano, 2008), and this
complex is an essential element in the CDKNA–CDK2 S phase.
SKP2 activates CDK2 and CDK1 by directing the degradation of
CDKN1 (p27) and CDKN1B (p21). SKP2 is also known to target
tumour suppressor proteins p21 and CDKN1C, resulting in protein
degradation (Frescas and Pagano, 2008). Activation and inactiva-
tion of CDKs is an additional crucial process, and dysregulation
may be involved in cell transformation. Other important kinases
include ABL1, a non-tyrosine kinase, that may regulate the CDC2
kinase (Lin et al, 2004), and PLK1, a cell cycle regulated kinase
(Yuan et al, 2002).
As cell cycle abnormalities have been observed in ovarian cancer
(Milde-Langosch and Riethdorf, 2003; De Meyer et al, 2009), we
hypothesized that common genetic variation in genes altering the
functionality of the molecules may influence the ovarian carcino-
genic process. An earlier study of 13 genes (88 informative
single nucleotide polymorphisms, SNPs) involved in regulation of
the G1–S phase of the cell cycle (CCNDA, CCND2, CCND3, CCNE1,
CDK2, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B,
CDKN2C and CDKN2D) found nominally significant associations
between SNPs in CDKN2A and CDKN1B [rs3731257 homozygous
minor vs homozygous major odds ratio, ORBB vs AA, 0.87 (95%
confidence interval, 95% CI, 0.73–1.03) P-value¼0.021; rs2066827
ORBB vs AA 0.79 (0.66–0.95) P-value¼0.04] (Gayther et al, 2007).
In addition, a combined analyses of 6 studies and 12 genes
including imputed genotypes found evidence of association with
selected SNPs in CDKN2A, CCND1, CDK2 and CCNE1, but not
in CDKN2C, CDKN1A, CCND3, CCND2, CDKN1B, CDK4, RB1,
CDKN2D or CDKN2B (Goode et al, 2009) Here, we report on a
more comprehensive two-stage analysis of the association of
ovarian cancer risk at 39 genes (288 SNPs) involved in G1/S and
G2/M phases of the cell cycle and transcription- and ubiquitin-
mediated degradation (Table 1).
MATERIALS AND METHODS
This study used a two-stage approach: a discovery set comprised of
two populations and a replication set comprised of four additional
populations. SNPs with suggestive statistical significance in the
discovery set were carried through to the replication set to validate
the results. Details for these sets and SNP selection are provided
below.
Discovery set
The discovery population comprised of 2051 women participating
in an ongoing ovarian cancer case–control study at the Mayo
Clinic (MAY) and Duke University (NCO) recruited between
June 1999 and March 2006, as described earlier (Kelemen et al,
2008; Sellers et al, 2008). Study protocols were approved by the
Institutional Review Boards at both institutions, and study
participants provided written informed consent. Cases were
women for whom a diagnosis of histologically confirmed primary
epithelial ovarian cancer was ascertained within 1 year of consent.
Information on known and suspected ovarian cancer risk factors
was collected by in-person interviews, including race/ethnicity,
menstrual and reproductive history, use of exogenous hormones,
medical and surgical history, tobacco use levels, education level,
height and weight 1 year before interview and family history
of breast and ovarian cancer in first- or second-degree relatives.
DNA was extracted from fresh peripheral blood using the Gentra
AutoPure LS Puregene salting out methodology (Gentra Inc,
Minneapolis, MN, USA). For NCO samples with limited DNA
available, WGA was performed using the REPLI-G protocol
(Qiagen) with 200ng genomic DNA as input yielding high
molecular weight DNA and reproducible genotype data (Cunning-
ham et al, 2008). Of the 2051 eligible participants, 1967 (95.6%)
Table 1 Cell cycle related genes
Gene family Role Genes studied
Cyclins Regulate CDK, CDC genes; G1/S, G2/M CCNA1, CCNA2, CCNB1, CCNB2,
CCND1, CCND2, CCND3, CCNE1,
CCNE2, CCNG1, CCNG2
Cyclin-dependent kinases Controlled by cylcins and INK4a; late G1/S CDK2, CDK4, CDK6, CDK7
Cell division cycle 2 Regulated by CCNA and CCNB cyclins; G1/S, G2M CDC2
Cell division cycle 25 homologues Activate CDC2, G1/S CDC25A, CDC25B
Cyclin-dependent kinase
inhibitors
Inhibit cyclin–CDK complexes; G1 CDKN1A, CDKN1B, CDKN2A, CDKN2B,
CDKN2C, CDKN2D
E2F transcription factor family E2F1, 2, 3 have cyclin-binding domains; most have tumour suppressor, transactivator
and dimerization domains; G1/S
E2F1, E2F2, E2F3, E2F4, E2F5, E2F6
Transcription factor Dimerization partners for E2F transcription factors TFDP1, TFDP2
Retinoblastoma-like genes Like RB, phosphorylated in S and M phases, dephosphorylated in G1, can inhibit
transcription of cell cycle genes containing E2F binding sites
RB1, RBL1, RBL2
Ubiquitin ligase complex SCF [SKP1-CUL1-F box] complex, essential element of CDKNA–CDK2 S-phase
kinase; SKP2 specifically phosphorylates CDKN1B in S phase
CUL1, SKP2
Other PLK1 may have a function in localization of CCNB1; ABL1 DNA binding regulated
by CDC2-mediated phosphorylation
PLK1, ABL1
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participants used in this report (829 cases and 941 controls).
Replication sets
Four case–control study populations were included in a replica-
tion analysis: the SEARCH ovarian cancer study from East Anglia,
United Kingdom (SEA), the MALOVA cancer study from Denmark
(MAL), the GEOCS study from Stanford University in Palo Alto,
CA (STA) and the UK OPS Study from the United Kingdom
(UKO). The SEA study (696 cases/1227 controls) included invasive
epithelial ovarian cancer cases collected from the East Anglian and
West Midlands cancer registries, and controls randomly selected
from European Prospective Investigation into Cancer and Nutri-
tion (EPIC) – Norfolk cohort study. The MAL study (439 cases/
1215 controls) contained invasive ovarian cancer cases and
population controls randomly drawn from a defined study area
in Denmark. The STA study (285 cases/364 controls) ascertained
participants from six counties in northern California including
invasive ovarian cancer cases and age-matched controls obtained
using random-digit dialling. The UKO study (269 cases/592
controls) drew cases from 10 gynaecologic oncology National
Health Service Centers and apparently healthy controls from the
UK Collaborating Trial of Ovarian Cancer Screening (UKCTOCS).
Additional replication study participant details are provided
elsewhere (Gayther et al, 2007; Ramus et al, 2008). Only white,
non-Hispanic participants were included.
Discovery SNP selection and genotyping
SNP selection for the discovery set involved identifying tagSNPs
for the 39 genes (Table 1; Supplemental Table 1). To accomplish
this, genotype data from the HapMap consortium http://hapmap.
org, Seattle SNPs http://pga.mbt.washington.edu, Perlegen Sciences
http://genome.perlegen.com and Panel 2 of the National Institute
for Environmental Health Sciences http://egp.gs.washingon.
edu were analysed with ldSelect (Carlson et al, 2004) to bin
SNPs with European American MAF 40.05 at a pairwise linkage
disequilibrium (LD) threshold of r
2 X0.8. The region for each gene
included 5kb upstream and downstream. Using these data, 288
tagSNPs and putative functional SNPs (non-synonymous coding
SNPs and SNPs altering splicing) for the 39 cell cycle genes were
included in one of two genotyping panels consisting of 2688 SNPs
as part of a larger genotyping effort (Supplementary Tables S1
and S2). Details about the Illumina GoldenGate genotyping have
been reported earlier (Cunningham et al, 2008; Kelemen et al,
2008; Sellers et al, 2008). Illumina design scores were 40.6 for
94.9% of the SNPs. Quality control data for the 288 cell cycle SNPs
are provided in Supplementary Table S2. SNP call rates were
40.95 and replicate concordance was 40.99.
Replication SNP selection and genotyping
SNPs with log-additive P-values o0.05 were considered for
replication. In addition, for SNPs not selected under the log-
additive model, but with a suggestion of association in either
dominant or recessive models, a more stringent threshold was
applied (P-value p0.03) for inclusion in the replication (statistical
methods described below). One of these SNPs (CDK2 rs2069414)
could not be genotyped using TaqMan, the replication platform,
and one of these SNPs (CCND3 rs3218086) was replaced by
rs3218092, which was in LD (r
2¼0.95) with rs3218086 and had
earlier been genotyped. Thus, six replication SNPs were genotyped
at the Strangeways Research Laboratory using TaqMan designed
assays, following the manufacturer’s recommended protocols;
rs3218092 had been similarly assayed (Gayther et al, 2007). Each
assay used 10ng DNA in a 5ml reaction volume with TaqMan
universal PCR Master Mix (Applied Biosystems, Warrington, UK);
primer and probe sequences, as well as assay conditions, are
available on request. TaqMan Allele Discrimination Sequence
Detection software (Applied Biosystems) was used to determine
genotype calls. SNP call rates were 40.95 and replicate
concordance was 40.99.
Statistical analyses
Discovery set participants were examined initially and restricted to
white, non-Hispanic participants. Departures from Hardy–Wein-
berg equilibrium (HWE) for each SNP were examined using
Pearson goodness-of-fit w
2 tests or, for SNPs with minor allele
frequencies o5%, exact tests (Weir, 1996). One SNP (rs12527393
in E2F3) had HWE P-value o0.001 among controls and was
excluded from analysis. Pairwise LD was estimated using r
2
statistics and graphically displayed using the Haploview v14.1
(Barrett et al, 2005). Unconditional logistic regression analysis was
used to estimate OR and 95% CI for risk of ovarian cancer
associated with each SNP. Primary tests of association assumed a
log-additive (multiplicative) genotypic effect, equivalent to the
Armitage test for trend. We also performed separate comparisons
of women with one copy (ORAB vs AA) and two copies (ORBB vs AA)
of the minor allele to women with no copies (reference). Secondary
analyses examined dominant and recessive SNP effects. All
analyses were adjusted for the design variables of age and
geographic region, as well as the following potential confounding
variables found to be associated with ovarian cancer risk in the
discovery set (P-value o0.05): body mass index, postmenopausal
hormone use, oral contraceptive use, parity and age at first birth.
Replication association testing was similarly carried out for each
SNP using unconditional logistic regression analyses as described
above. Associations were examined by site, as well as combined
across sites, adjusting for age. Analyses were conducted including and
excluding the discovery set participants, adjusting for age and study
site. Two sets of P-values were calculated for the replication set: one
based on the simple comparison-wise error rate and one accounting
for the number of replication tests using a Bonferroni correction.
Results
Distributions of risk factor information for the discovery set have
been described earlier (Sellers et al, 2005; Kelemen et al, 2008).
Generally, case–control differences were similar across both
discovery sites: overall, cases tended to be more obese, have lower
parity, reported a greater family history of ovarian cancer and were
more likely to have used hormone therapy (NCO site) or oral
contraceptives (MAY site). Of the 288 SNPs attempted, 269 (93.4%)
passed quality control and were included in the analysis. Eleven
variants in nine genes showing significance at P-value o0.05 for
adjusted (multivariate) analyses using log-additive (ordinal), recessive
or dominant models are shown in Table 2. Assuming a log-additive
model, variants in five genes revealed significant associations (P-value
o0.05): ABL1 rs2855192, CDKN1A rs776246, CCND3 rs3218086,
CDK2 rs2069414 and E2F3 rs7760528. SNPs in two of these genes
(ABL1 and E2F3) revealed additional evidence of a recessive effect,
whereas SNPs in CDKN1A, CCND3 and CDK2 revealed additional
evidence of a dominant association (Table 2). Although our analysis
used the log-additive model as the primary analysis, there were two
additional SNPs, rs2448343 in CDC2 and rs12656449 in CDK7,w i t h
non-significant P-values in the log-additive model, but significant
P-values using a recessive model: OR 0.67 (95% CI 0.50–0.89),
P¼0.006 and OR 2.91 (95% CI 1.11–8.05) P¼0.03, respectively.
CCNB2 rs1486878 (OR 1.50, 95% CI 1.05–2.15) also suggested
association only with a recessive model (P¼0.04).
Eight of the 11 significant SNPs were chosen for replication.
These included ABL1 rs2855192, CDKN1A rs7767246, CCND3
rs3218086 (which was substituted with rs3218092, r
2 0.95), E2F3
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because of lack of TaqMan assay conversion) based on the log-
additive model P-value o 0.05, E2F2 rs760607 based on dominant
model, P-value of 0.02, and CDC2 rs2448343 and CDK7 rs12656449
based on recessive model, P-value of 0.01 and 0.03, respectively, in
the discovery set analysis (Table 2). Table 3 provides results
for site-specific and combined replication analyses. For one SNP,
rs2855192 in ABL1, the results were similar to those obtained
in the discovery sample set, in one of the four sites (STA), with a
log-additive increase in risk (P-value¼0.03, Table 3; Figure 1) and
also consistent with a recessive effect. Combined analysis of
all sites revealed a suggestion of a recessive association (OR for
homozygous minor allele genotypes compared with homozygous
major allele, ORBB vs AA 1.59, 95% CI 1.08–2.34, P-value¼0.02).
Excluding the discovery sites, this association was attenuated
(OR 1.40, 95% CI 0.89–2.19, P-value¼0.14) (Table 3). E2F3
rs776052 was associated with ovarian cancer risk in one replication
population (UKO), but did not remain significant in the combined
analysis. CDKN1A rs776246 and CDC2 rs2448343 were associated
with risk in one population each (MAL and OPS, respectively), but
the risk estimates were in the opposite direction to that found in the
discovery set and not considered replications. CDC2 rs2448343 was
significantly associated using all datasets assuming a recessive model
only. None of the replication results remained statistically significant
after correction for multiple testing (data not shown). For SNPs in
CCND3, CDK7, E2F2 and E2F3, no replication of the initial result was
seen in any of the replication sites, and the combined analysis did
not reveal any significant findings (Table 3; Figure 1).
Discussion
This study used a two-stage approach to assess the contribution of
inherited variation in 39 cell cycle genes to the risk of epithelial
ovarian cancer and found some evidence of association at ABL1
rs2855192. Cell cycle dysregulation is a hallmark of the malignant
state, and the function of genetic variation in cell cycle genes,
including in ovarian cancer, has been reported in a number of
studies (Gayther et al, 2007; Goode et al, 2009); this study extends
the prior findings by the inclusion of an additional 26 and 28
additional genes, respectively. In the discovery set, SNPs in several
genes were found to be associated with the risk of ovarian cancer;
of these, five genes (ABL1, CCND3, CDKN1A, E2F3 and CDK2)
were significant in log-additive models (P-value o0.05). This
study also found four additional variants in CCNB2, CDC2, CDK7
and E2F2 (rs3328203) to be significant assuming a recessive model
only. One additional variant in E2F2 (rs76067) was found to be
associated assuming a dominant model, but not in the log-additive
model. Replication testing of seven SNPs revealed one SNP in
ABL1 to have an association in one of the four replication
populations assessed (also from the US) and was significant overall
with a recessive model. However, once adjustments for multiple
comparisons were made, no significant association was noted for
any variant.
ABL1 is a ubiquitously expressed, non-tyrosine kinase, encoding
both cytoplasmic and nuclear kinases (Preyer et al, 2007). The
ABL1 gene is expressed as either a 6 or 7kb mRNA transcript, with
alternatively spliced first exons spliced to exons 2–11. ABL1 has
been implicated in processes of cell differentiation, cell division,
cell adhesion and cellular stress response (Wang, 1993; Kharbanda
et al, 1995; Lewis et al, 1996; Barila and Superti-Furga, 1998).
A t(9;22) translocation, which results in the head-to-tail fusion of
the BCR and ABL1 genes, is present in many cases of chronic
myelogeneous leukaemia (De Keersmaecker and Cools, 2006). The
DNA-binding activity of ABL1 tyrosine kinase is regulated by
CDC2-mediated phosphorylation, suggesting a cell cycle function
for ABL1 (Welch and Wang, 1993). The tyrosine kinase activity
of nuclear ABL1 is regulated in the cell cycle through a specific
Table 2 Discovery set: cell cycle SNPs and ovarian cancer risk (Po0.05)
Samples** Log-additive Heterozygote Homozygote rare allele P-values
Gene/SNP ID Cases Controls OR (95% CI) OR (95% CI) OR (95% CI) Log-additive Dominant Recessive
ABL1
rs2855192 825 940 1.26 (1.03–1.55) 1.14 (0.90–1.44) 2.81 (1.29–6.09) 0.02 0.09 0.01
CCNB2
rs1486878 829 939 1.14 (0.98–1.33) 1.04 (0.85–1.27) 1.53 (1.06–2.21) 0.08 0.31 0.04
CCND3
rs3218086 827 941 1.23 (1.03–1.47) 1.18 (0.95–1.47) 1.75 (1.01–3.03) 0.02 0.05 0.07
CDKN1A
rs7767246 826 941 0.83 (0.69–0.99) 0.83 (0.67–1.02) 0.69 (0.40–1.20) 0.04 0.04 0.28
CDC2
rs2448343 828 935 0.91 (0.79–1.05) 1.13 (0.91–1.39) 0.71 (0.52–0.97) 0.20 0.88 0.01
CDK2
rs2069414 821 930 1.36 (1.03–1.78) 1.36 (1.02–1.81) 1.70 (0.27–10.83) 0.03 0.03 0.60
CDK7
Rs12656449 828 941 1.02 (0.8–1.29) 0.86 (0.66–1.13) 2.91 (1.08–7.86) 0.90 0.61 0.03
E2F2
rs3218203 827 941 1.12 (0.95–1.32) 1.01 (1.08–1.25) 1.62 (1.02–2.59) 0.18 0.47 0.04
rs760607 824 941 0.87 (0.75–1.00) 0.78 (0.63–0.97) 0.81 (0.60–1.08) 0.05 0.02 0.57
E2F3
rs7760528 828 940 0.86 (0.75–1.00) 0.93 (0.75–1.14) 0.69 (0.50–0.97) 0.05 0.18 0.04
rs2328524 829 941 0.88 (0.76–1.01) 0.83 (0.67–1.02) 0.79 (0.59–1.07) 0.06 0.05 0.35
Multivariate logistic hormone replacement therapy, parity and body mass index; P-values o0.05 are in bold type, as are CIs that exclude 1.0.
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cytoplasm, ABL1 responds to growth factor and adhesion signals
to regulate F-actin dynamics (Woodring et al, 2003). As acquired
resistance to imatinib is associated with mutations in the kinase
domain of BCR-ABL that interferes with drug binding, it may
be possible that a coding SNP in ABL1 modulates the imatinib
response (Crossman et al, 2005). The associated SNP, rs2855192,
is in intron 1 and the functional aspects are unknown; this SNP
was a tagSNP, but did not tag any other SNPs (i.e. it was in a
singleton bin with r
2o0.8 with other HapMap SNPs). ABL1 was
included in this study because of its function in cell cycle function;
however, the cytoplasmic form of ABL1 may have a function in
cell adhesion in addition to DNA binding when localized to the
nucleus.
In an earlier study, variants in CDKN1B and CDKNA2/2B were
found to be associated with ovarian cancer risk in a combined
analysis of 3601 cases and 5705 controls (Gayther et al, 2007). In
this study, no variant in either of these genes was significant in the
Table 3 Discovery and replication sets: cell cycle SNPs and ovarian cancer risk
Genotyped samples Log-additive Heterozygote Homozygote rare allele P-values
Gene/SNP ID Case Control OR (95% CI) OR (95% CI) OR (95% CI) Log-additive Dominant Recessive
ABL1 rs2855192
MAL 431 1199 1.04 (0.82–1.32) 1.14 (0.87–1.49) 0.62 (0.23–1.68) 0.75 0.51 0.32
SEA 693 1219 0.86 (0.71–1.05) 0.77 (0.62–0.97) 1.46 (0.69–3.08) 0.14 0.05 0.24
STA 284 364 1.42 (1.05–1.93) 1.21 (0.83–1.76) 3.73 (1.30–10.7) 0.03 0.09 0.02
UKO 265 579 1.23 (0.89–1.69) 1.29 (0.91–1.84) 0.94 (0.23–3.91) 0.21 0.17 0.86
Combined replication 1673 3361 1.04 (0.92–1.18) 1.00 (0.87–1.15) 1.40 (0.89–2.19) 0.48 0.73 0.14
Combined all 2322 4269 1.08 (0.97–1.21) 1.03 (0.91–1.16) 1.59 (1.08–2.34) 0.14 0.35 0.02
CCND3 rs3218086
MAL 424 1186 1.14 (0.94–1.39) 1.21 (0.95–1.54) 1.08 (0.61–1.93) 0.19 0.12 0.96
SEA 594 849 0.96 (0.78–1.17) 1.02 (0.81–1.29) 0.69 (0.35–1.35) 0.67 0.92 0.26
STA 283 363 0.84 (0.64–1.10) 0.92 (0.65–1.31) 0.56 (0.26–1.22) 0.21 0.38 0.16
UKO – – ––
Combined replication 1301 2398 1.00 (0.89–1.14) 1.07 (0.92–1.25) 0.81 (0.55–1.91) 0.95 0.59 0.23
Combined all 1951 3307 1.09 (0.98–1.21) 1.12 (0.99–1.27) 1.07 (0.79–1.46) 0.10 0.07 0.83
CDC2 rs2448343
MAL 419 1159 1.02 (0.87–1.20) 1.08 (0.85–1.38) 0.99 (0.69–1.41) 0.83 0.61 0.77
SEA 691 1212 0.95 (0.82–1.09) 0.99 (0.81–1.21) 0.87 (0.64–1.17) 0.45 0.68 0.35
STA 279 359 1.14 (0.90–1.44) 1.12 (0.80–1.57) 1.31 (0.78–2.20) 0.28 0.37 0.40
UKO 252 571 0.80 (0.63–1.01) 0.69 (0.49–0.98) 0.71 (0.43–1.16) 0.06 0.03 0.50
Combined replication 1640 3301 0.97 (0.89–1.06) 0.99 (0.87–1.13) 0.92 (0.76–1.10) 0.48 0.70 0.39
Combined all 2290 4204 0.96 (0.89–1.04) 1.05 (0.94–1.17) 0.87 (0.73–1.03) 0.32 0.96 0.04
CDK7 rs12656449
MAL 434 1205 0.98 (0.75–1.29) 1.01 (0.75–1.35) 0.75 (0.21–2.74) 0.90 0.97 0.66
SEA 692 1220 1.06 (0.84–1.33) 1.12 (0.88–1.45) 0.57 (0.18–1.83) 0.64 0.46 0.33
STA 283 361 0.83 (0.55–1.27) 0.83 (0.52–1.34) 0.70 (0.11–4.23) 0.40 0.41 0.71
UKO 258 470 1.17 (0.78–1.75) 1.16 (0.76–1.77) 1.64 (0.15–18.2) 0.45 0.47 0.70
Combined replication 1667 3356 1.01 (0.87–1.17) 1.05 (0.89–1.23) 0.69 (0.33–1.44) 0.89 0.70 0.31
Combined all 2318 4265 1.01 (0.89–1.14) 0.99 (0.86–1.14) 1.19 (0.69–2.05) 0.90 0.98 0.53
CDKN1A rs776246
MAL 428 1202 1.21 (1.00–1.46) 1.28 (1.01–1.63) 1.26 (0.73–2.16) 0.05 0.04 0.59
SEA 691 1216 0.97 (0.82–1.14) 1.02 (0.83–1.25) 0.78 (0.47–1.30) 0.68 0.94 0.33
STA 284 355 1.17 (0.89–1.55) 1.18 (0.84–1.65) 1.37 (0.59–3.13) 0.26 0.28 0.54
UKO 262 575 0.97 (0.73–1.28) 1.10 (0.78–1.55) 0.61 (0.24–1.54) 0.81 0.86 0.26
Combined replication 1665 3348 1.08 (0.97–1.20) 1.14 (1.00–1.30) 0.98 (0.72–1.34) 0.15 0.07 0.71
Combined all 2314 4257 1.01 (0.92–1.10) 1.05 (0.94–1.18) 0.88 (0.67–1.16) 0.86 0.54 0.31
E2F2 rs760607
MAL 421 1159 0.91 (0.77–1.07) 0.89 (0.70–1.14) 0.83 (0.58–1.20) 0.25 0.27 0.48
SEA 692 1221 0.99 (0.86–1.13) 0.99 (0.80–1.21) 0.98 (0.73–1.31) 0.87 0.87 0.92
STA 281 346 1.21 (0.97–1.52) 1.19 (0.83–1.69) 1.48 (0.93–2.35) 0.09 0.17 0.16
UKO 261 574 1.12 (0.89–1.40) 0.88 (0.62–1.25) 1.40 (0.89–2.20) 0.33 0.99 0.06
Combined replication 1655 3300 1.01 (0.93–1.10) 0.94(0.83–1.08) 1.06 (0.88–1.27) 0.80 0.70 0.30
Combined all 2304 4209 0.98 (0.91–1.05) 0.91 (0.81–1.02) 1.00 (0.86–1.17) 0.58 0.19 0.48
E2F3 rs7760528
MAL 426 1200 1.04 (0.89–1.24) 1.08 (0.85–1.36) 1.07 (0.73–1.56) 0.58 0.53 0.86
SEA 692 1215 0.94 (0.81–1.08) 1.01 (0.83–1.24) 0.80 (0.57–1.11) 0.36 0.74 0.15
STA 282 361 0.99 (0.79–1.25) 1.03 (0.74–1.44) 0.97 (0.58–1.61) 0.99 0.91 0.84
UKO 259 576 1.24 (0.97–1.57) 1.01 (0.73–1.43) 1.85 (1.10–3.11) 0.08 0.38 0.02
Combined replication 1659 3352 1.01 (0.93–1.11) 1.04 (0.91–1.17) 1.00 (0.82–1.23) 0.77 0.64 0.90
Combined all 2309 4260 0.96 (0.89–1.04) 0.99 (0.89–1.11) 0.89 (0.75–1.07) 0.34 0.62 0.21
Logistic regression analysis adjusting for age and, for combined results, study site; P-values p0.05 and CIs that exclude 1.0 are in bold type; combined all indicates discovery plus
replication sets; CCND3 rs32189092 was substituted for CCND3 rs3218086 in replication sets.
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sdiscovery set (Supplementary Table S2) and so were not carried
forward to the replication phase. In another study using imputed
genotypes, based on data from five independent ovarian cancer
studies (Goode et al, 2009), the signal observed for CDNKN1A in
the MAYþNCO dataset was not supported by imputation of
genotypes in the other four studies, consistent with the replication
data in this report. For rs2069391 in CDK2 variant, which could not
be genotyped in the replication set in this study (discovery set log-
additive OR 1.36, CI 1.03–1.78), imputation revealed a signal in the
earlier combined analysis (log-additive OR 1.21, CI 1.01–2.09),
which included five of the six populations in this study (Goode
et al, 2009).
A strength of this study was its comprehensive nature in terms
of the number of genes and number of tagSNPs and inclusion of
putatively functional SNPs. Owing to a large number of tests (269
SNPs 3 genetic modes of inheritance), caution in interpreting
the data is warranted; no adjustment was made for multiple
testing because of a lack of complete independence of tests. An
additional strength of this study is the inclusion of four replication
populations, which improves power (Ioannidis et al, 2001; Morgan
et al, 2007), although replication genotyping of only the top 2% of
SNPs limited the power of our two-stage approach. In recent meta-
analyses and pooled analyses 161 cancer genetic association
studies (Dong et al, 2008), close to one-third of all associations
were reported to be statistically significant and many of the
false positive associations arose from small studies with multiple
subset analyses. Therefore, we consider this analysis a preliminary
screen of the cell cycle pathway and one which indicates modest
SITE
All subjects 1.03 (0.91, 1.16)
UKO 1.29 (0.91, 1.84)
STA 1.21 (0.83, 1.76)
SEA 0.77 (0.62, 0.97)
MAL 1.14 (0.87, 1.49)
NCO 1.14 (0.82, 1.60)
MAY 1.07 (0.74, 1.54)
0.13 0.25 0.50 1.00 2.00 4.00 8.00 16.00 32.00
OR (95% Cl)
SITE
All subjects 1.59 (1.08, 2.34)
UKO 0.94 (0.23, 3.9)
STA 3.73 (1.30, 10.71)
SEA 1.46 (0.69, 3.08)
MAL 0.62 (0.23, 1.68)
NCO 1.38 (0.49, 3.88)
MAY 1.07 (0.74, 1.54)
0.13 0.25 0.50 1.00 2.00 4.00 8.00 16.00 32.00
OR (95% Cl)
Figure 1 Study-specific and combined OR and 95% CI for ABL1 rs2855192. Analyses of all subjects adjusted for age and study site; study-specific analyses
adjust only for age. (A) Heterozygous vs homozygous major allele participants (ORAB vs AA). (B) Homozygous minor allele vs homozygous major participants
(ORBB vs AA).
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sevidence for association with disease risk for only one gene,
ABL1. Additional examination of ABL1 rs2855192, and including
other SNPs with suggestive discovery set results, is warranted in
additional studies within the ovarian cancer consortium (Ramus
et al, 2008).
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